日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

更正：ALRN-6924（一种MDMX和MDM2双重抑制剂）在携带野生型TP53的实体瘤和淋巴瘤患者中的I期试验

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-4241
Saleh, Mansoor N; Patel, Manish R; Bauer, Todd M; Goel, Sanjay; Falchook, Gerald S; Shapiro, Geoffrey I; Chung, Ki Y; Infante, Jeffrey R; Conry, Robert M; Rabinowits, Guilherme; Hong, David S; Wang, Judy S; Steidl, Ulrich; Walensky, Loren D; Naik, Gurudatta; Guerlavais, Vincent; Vukovic, Vojislav; Annis, D Allen; Aivado, Manuel; Meric-Bernstam, Funda
MDM2
淋巴瘤
P53
ALR
发表日期：2022
文献求助 收藏

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

p53的药理学激活可触发病毒模拟反应，从而消除肿瘤免疫逃逸并促进抗肿瘤免疫。

期刊:Cancer Discovery
影响因子:33.3
doi:10.1158/2159-8290.CD-20-1741
Zhou, Xiaolei; Singh, Madhurendra; Sanz Santos, Gema; Guerlavais, Vincent; Carvajal, Luis A; Aivado, Manuel; Zhan, Yue; Oliveira, Mariana M S; Westerberg, Lisa S; Annis, D Allen; Johnsen, John Inge; Selivanova, Galina
微生物学
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2021
文献求助 收藏

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

ALRN-6924（一种MDMX和MDM2双重抑制剂）在携带野生型TP53的实体瘤和淋巴瘤患者中的I期临床试验

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-21-0715
Saleh, Mansoor N; Patel, Manish R; Bauer, Todd M; Goel, Sanjay; Falchook, Gerald S; Shapiro, Geoffrey I; Chung, Ki Y; Infante, Jeffrey R; Conry, Robert M; Rabinowits, Guilherme; Hong, David S; Wang, Judy S; Steidl, Ulrich; Naik, Gurudatta; Guerlavais, Vincent; Vukovic, Vojislav; Annis, D Allen; Aivado, Manuel; Meric-Bernstam, Funda
MDM2
淋巴瘤
P53
ALR
发表日期：2021
文献求助 收藏

First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

首创双重 MDM2/MDMX 抑制剂 ALRN-6924 可增强 TP53 野生型激素受体阳性乳腺癌模型中化疗的抗肿瘤疗效

期刊:Breast Cancer Research
影响因子:6.1
doi:10.1186/s13058-021-01406-x
Seyed Pairawan, Ming Zhao, Erkan Yuca, Allen Annis, Kurt Evans, David Sutton, Luis Carvajal, Jian-Guo Ren, Solimar Santiago, Vincent Guerlavais, Argun Akcakanat, Coya Tapia, Fei Yang, Priya Subash Chandra Bose, Xiaofeng Zheng, Ecaterina Ileana Dumbrava, Manuel Aivado, Funda Meric-Bernstam
肿瘤
乳腺癌
WB
发表日期：2021
文献求助 收藏

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models

通过临床前模型鉴定的T细胞和NK细胞淋巴瘤中的可靶向脆弱性

期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-018-04356-9
Samuel Y Ng ，Noriaki Yoshida ，Amanda L Christie ，Mahmoud Ghandi ，Neekesh V Dharia ，Joshua Dempster ，Mark Murakami ，Kay Shigemori ，Sara N Morrow ，Alexandria Van Scoyk ，Nicolas A Cordero ，Kristen E Stevenson ，Maneka Puligandla ，Brian Haas ，Christopher Lo ，Robin Meyers ，Galen Gao ，Andrew Cherniack ，Abner Louissaint Jr ，Valentina Nardi ，Aaron R Thorner ，Henry Long ，Xintao Qiu ，Elizabeth A Morgan ，David M Dorfman ，Danilo Fiore ，Julie Jang ，Alan L Epstein ，Ahmet Dogan ，Yanming Zhang ，Steven M Horwitz ，Eric D Jacobsen ，Solimar Santiago ，Jian-Guo Ren ，Vincent Guerlavais ，D Allen Annis ，Manuel Aivado ，Mansoor N Saleh ，Amitkumar Mehta ，Aviad Tsherniak ，David Root ，Francisca Vazquez ，William C Hahn ，Giorgio Inghirami ，Jon C Aster ，David M Weinstock ，Raphael Koch
细胞生物学
T细胞
免疫/内分泌
淋巴瘤
T细胞
发表日期：2018
文献求助 收藏

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

非肽类血小板生成素受体激动剂艾曲波帕对急性髓系白血病和骨髓增生异常综合征患者骨髓细胞的影响

期刊:Blood
影响因子:21
doi:10.1182/blood-2009-04-219493
Britta Will, Masahiro Kawahara, Julia P Luciano, Ingmar Bruns, Samir Parekh, Connie L Erickson-Miller, Manuel A Aivado, Amit Verma, Ulrich Steidl
免疫
细胞生物学
白血病
血小板
发表日期：2009
文献求助 收藏